November 3, 2021, Singapore – Evive Biotech, a global biologics company developing novel biologic therapies, today announces the grand opening of the company's new R&D center in San Francisco Bay Area. Situated in the Biotech Bay, the EWING center will focus on development of antibody therapeutics, with function groups in antibody discovery and engineering, protein science, discovery biology research, in vivo pharmacology, preclinical safety assessment and PKPD, and project management.

 

 

Evive Biotech's new R&D center in San Francisco Bay Area

 

“With the launch of EWING center, we are significantly accelerating our exploration, discovery and advancement of novel therapies,” said Jubo Liu, CEO of Evive Biotech. “A complete chain has been formed from early-stage discovery to translational medicine to help quickly and safely bring our pipeline therapies to the end-patient. With the coordination and cooperation of our global clinical teams, we will be able to support the sustainable development of Evive's clinical assets.”

 

“The bay area is known for its biotech industry, its innovative, diverse culture, and talents,” said Laura Sun, Senior VP, Global Head of R&D. “The opening of EWING demonstrates the commitment of Evive in its mission, as a global company, to develop innovative therapies that address unmet medical needs and benefit patients worldwide.”

 

Lichuan Liu, Senior VP, Global Head of Translational Science commented, “This new R&D center is going to provide momentum for innovation at Evive globally. We will work together to establish a sustainable and strong pipeline and bring the best in class/first in class products into the global market.”

 

The San Francisco Bay Area is home to thousands of biotech and pharmaceutical R&D centers. The newly launched EWING is a critical component of Evive’s R&D powerhouse which includes the Evive Maryland EGG R&D Center which focuses on bioanalytical assay development and related protein biochemistry and the Shanghai EGROW R&D Center which focuses on development of Fc fusion protein therapies (DiKine) and early cell line development.

 

About Evive Biotech

 

Evive Biotech is a global biologics company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

 

To learn more about Evive Biotech, visit www.evivebiotech.com.